Californian biotech, Jasper Therapeutics, has expanded its Series A financing with an additional investment of $14.1 million led by Roche Venture Fund.
The expansion, which also saw participation from other investors, brings the company’s total financing to over $50 million to date.
The proceeds will be used to advance and expand the study of Jasper’s lead clinical asset, JSP191.
A humanised antibody targeting CD117 on hematopoietic stem cells, JSP191 is designed to replace toxic chemotherapy and radiation therapy as conditioning regimens to prepare patients for curative stem cell and gene therapy.
JSP191 is the only antibody of its kind in clinical development as a single conditioning agent for people undergoing curative hematopoietic cell transplantation.
This investigational agent is currently being evaluated in a Phase 1/2 dose-escalation and expansion study as a conditioning agent to enable stem cell engraftment in patients with severe combined immunodeficiency (SCID) who received a prior stem cell transplant that resulted in poor outcome.
Initial positive results from this ongoing clinical trial were presented in an oral session in December 2019.
Jasper plans to expand the Phase 1/2 clinical study to include patients with acute myeloid leukaemia or myelodysplastic syndromes receiving hematopoietic cell transplant.
The development of JSP191 is supported by a collaboration with the California Institute for Regenerative Medicine (CIRM).